GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » FibroGen Inc (NAS:FGEN) » Definitions » Cyclically Adjusted PB Ratio

FibroGen (FibroGen) Cyclically Adjusted PB Ratio : 0.36 (As of May. 26, 2024)


View and export this data going back to 2014. Start your Free Trial

What is FibroGen Cyclically Adjusted PB Ratio?

As of today (2024-05-26), FibroGen's current share price is $1.30. FibroGen's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $3.61. FibroGen's Cyclically Adjusted PB Ratio for today is 0.36.

The historical rank and industry rank for FibroGen's Cyclically Adjusted PB Ratio or its related term are showing as below:

FGEN' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.11   Med: 0.5   Max: 6.84
Current: 0.36

During the past years, FibroGen's highest Cyclically Adjusted PB Ratio was 6.84. The lowest was 0.11. And the median was 0.50.

FGEN's Cyclically Adjusted PB Ratio is ranked better than
77.79% of 653 companies
in the Biotechnology industry
Industry Median: 1.73 vs FGEN: 0.36

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

FibroGen's adjusted book value per share data for the three months ended in Mar. 2024 was $-2.293. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $3.61 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


FibroGen Cyclically Adjusted PB Ratio Historical Data

The historical data trend for FibroGen's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FibroGen Cyclically Adjusted PB Ratio Chart

FibroGen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 4.47 0.24

FibroGen Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.92 0.73 0.24 0.24 0.65

Competitive Comparison of FibroGen's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, FibroGen's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


FibroGen's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, FibroGen's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where FibroGen's Cyclically Adjusted PB Ratio falls into.



FibroGen Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

FibroGen's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=1.30/3.61
=0.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

FibroGen's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, FibroGen's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-2.293/131.7762*131.7762
=-2.293

Current CPI (Mar. 2024) = 131.7762.

FibroGen Quarterly Data

Book Value per Share CPI Adj_Book
201406 -3.462 100.560 -4.537
201409 -4.005 100.428 -5.255
201412 3.750 99.070 4.988
201503 3.115 99.621 4.120
201506 4.201 100.684 5.498
201509 3.548 100.392 4.657
201512 2.864 99.792 3.782
201603 2.514 100.470 3.297
201606 3.078 101.688 3.989
201609 2.828 101.861 3.659
201612 2.448 101.863 3.167
201703 2.044 102.862 2.619
201706 3.242 103.349 4.134
201709 6.985 104.136 8.839
201712 6.406 104.011 8.116
201803 5.988 105.290 7.494
201806 5.886 106.317 7.296
201809 5.555 106.507 6.873
201812 5.960 105.998 7.409
201903 5.680 107.251 6.979
201906 7.243 108.070 8.832
201909 6.816 108.329 8.291
201912 5.888 108.420 7.156
202003 5.156 108.902 6.239
202006 4.387 108.767 5.315
202009 4.970 109.815 5.964
202012 4.617 109.897 5.536
202103 4.029 111.754 4.751
202106 2.814 114.631 3.235
202109 3.514 115.734 4.001
202112 2.252 117.630 2.523
202203 1.694 121.301 1.840
202206 1.107 125.017 1.167
202209 0.280 125.227 0.295
202212 -0.228 125.222 -0.240
202303 -0.506 127.348 -0.524
202306 -1.041 128.729 -1.066
202309 -1.598 129.860 -1.622
202312 -2.067 129.419 -2.105
202403 -2.293 131.776 -2.293

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


FibroGen  (NAS:FGEN) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


FibroGen Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of FibroGen's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


FibroGen (FibroGen) Business Description

Industry
Traded in Other Exchanges
Address
409 Illinois Street, San Francisco, CA, USA, 94158
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.
Executives
Jeffrey William Henderson director 7000 CARDINAL PLACE, DUBLIN OH 43017
Enrique A Conterno director, officer: Chief Executive Officer LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Thane Wettig officer: Chief Commercial Officer C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Christine Chung officer: SVP, China Operations C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Jeffrey L Edwards director 2525 DUPONT DR, IRVINE CA 92612
Aoife Brennan director 200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139
Benjamin Cravatt director C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Suzanne Blaug director C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Maykin Ho director C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
James A Schoeneck director C/O DEPOMED, INC., 1360 O'BRIEN DRIVE, MENLO PARK CA 94025
Mark Eisner officer: Incoming Chief Medical Officer C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Juan Graham officer: Chief Financial Officer C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Kearns Thomas F Jr director P O BOX 587, WARSAW IN 46581-0587
Pat Controneo officer: VP, Finance and CFO C/O FIBROGEN, INC., 409 ILLINOIS ST.,, SAN FRANCISCO CA 94158
Kalevi Kurkijarvi director C/O FIBROGEN, INC., 409 ILLINOIS ST.,, SAN FRANCISCO CA 94158